Business Wire

Indivumed and Biognosys Extend Strategic Partnership

Share

Indivumed, developer of the world’s leading discovery platform for precision oncology, and Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, announced today that they are extending their strategic partnership to provide biopharma customers with immunopeptidomics insights for oncology drug discovery.

The partnership is driven by each company’s unique capabilities in omics research, with Biognosys bringing industry-leading mass spectrometry-based proteomics technology and solutions, and Indivumed providing high-quality samples and data as well as its multi-omics based AI discovery system, nRavel®.

The initial partnership established in December 2019 focused on enriching Indivumed’s IndivuType multi-omics cancer database with proteome-level data from thousands of samples analyzed by Biognosys. Since then, Indivumed and Biognosys have successfully collaborated on various clinical research projects and published results from a large-scale study in lung cancer at AACR 2020, revealing new biomarkers for tumor biology. Building on this success, the companies are now extending their partnership with immunopeptidomics research.

Immunopeptides play an essential role in the immune system and can be analyzed to support the development of personalized treatments, especially in cancers, vaccines, infectious, and autoimmune diseases. Mass spectrometry is currently the only technology that can reliably measure and identify immunopeptide profiles of biological samples on a large scale.

Biognosys’ immunopeptidomics workflow deploys its patented Hyper Reaction Monitoring (HRM™) mass spectrometry technology for proteome quantification in combination with its proprietary Spectronaut™ and SpectroMine™ data analysis software to identify over 10,000 unique immunopeptides from low amounts of sample material. The workflow is highly efficient and scalable for use in large-scale clinical studies.

Indivumed then can provide biopharma customers further validation and insights on the immunopeptide signatures identified through Biognosys’ workflow, based on its IndivuType, global multi-omics cancer database and its analytics platform nRavel® to enhance R&D activities and new discovery programs for individualized therapy.

Biognosys will present validation of the workflow sensitivity and reproducibility at the American Society of Mass Spectrometry (ASMS) Annual Conference on Nov 1st in Philadelphia, while Indivumed will present clinically relevant multi-omic analysis at the BioData World Congress on Nov 2nd in Basel.

The new immunopeptidomics offering is already being applied successfully with third party biopharma companies to enhance their drug discovery efforts.

Lukas Reiter, PhD, Chief Technology Officer of Biognosys states: “Biognosys’ HRM technology uniquely addresses key challenges in immunopeptidomics research. Using only small amounts of tissue, our optimized workflow provides deep and comprehensive biological insights on the immune system. We are thrilled to apply this solution on the valuable tissue samples from Indivumed and support drug discovery in areas of high unmet need.”

Roald Forsberg, Chief Business Officer and Head of IndivuType Business Unit at Indivumed commented: “With our unique IndivuType database and our nRavel® AI system we have a fantastic opportunity to make new discoveries regarding the role of the immune response in the tumor microenvironment and to develop new immunotherapies against cancer. This extended partnership with Biognosys gives us the ability to validate and expand our findings using state-of-the-art mass-spectrometry technology which will accelerate our path towards bringing these discoveries into the practice of personalized oncology.”

About Biognosys

Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.

About Indivumed

Driven by our mission to unveil the complex mechanisms of cancer and to advance precision oncology, Indivumed combines the world’s most comprehensive multi-omics data with extensive medical experience, bioinformatics expertise, and AI-integrated advanced analytics. Our global clinical network enables us to collect and analyze thousands of patient samples using a standardized approach to ensure biospecimen quality across three business units – IndivuServ, IndivuTest, and IndivuType. The unparalleled depth and quality of our data – coupled with our robust product and service offerings – gives us the ability to obtain novel insights and accelerate cancer research. For more information, visit www.indivumed.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact Biognosys
Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com

Media Contact Indivumed
Kristin Maack
Senior Director Marketing & Corporate Communications
Phone +49 41 33 83 71
press@indivumed.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Forty Years on From the Start of the HIV Epidemic, New Data Reveals People Living With HIV Face Outdated Attitudes and Ongoing Discrimination1.12.2021 03:01:00 EET | Press release

Pervasive stigma and prejudice towards people living with HIV continues to persist, according to a new international survey released today on World AIDS Day. Funded by ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline Plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, the survey uncovers outdated attitudes and inherent bias amongst the general public towards people living with HIV. An overwhelming majority (88%) of respondents believe there are still negative perceptions towards people living with HIV, even though it can now be effectively managed with antiretroviral (ARV) medication. Concerningly, almost a third (30%) of people surveyed incorrectly believe HIV can be transmitted through kissing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006152/en/ The survey, conducted online by The Harris Poll, surveyed 5,047 adults across four countries, Australia, Portugal, U

Japan Domestic Flights Scheduled for Recovery in Q1 2022: Cirium Survey Reveals Sapporo and Okinawa as Top Destinations1.12.2021 03:00:00 EET | Press release

The majority of Japanese travelers intend to take to the skies again, with 80% planning to travel in the next 12 months for leisure purposes (83%) and to domestic destinations, according to the new Cirium Traveler Intelligence Report. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130006033/en/ Aviation analytics company Cirium records a noticeable increase in intention to travel across other markets surveyed, while travelers in Japan continue to be wary of the potential risks from COVID-19. International travel is likely to remain difficult, however, there are encouraging indicators of recovery in Japanese domestic markets. Cirium data shows domestic traffic in Japan at 54% of 2019 levels, above the 49% average seen across APAC domestic markets excluding China. Additionally, Cirium schedules data shows Japan is projected to reach 93% of 2019 Q1 traffic in the first quarter of 2022. The recovery of international flights c

Andersen Global Enters the Bolivian Market1.12.2021 02:16:00 EET | Press release

Andersen Global expands its Latin American coverage through a Collaboration Agreement with Bolivia-based law firm Indacochea & Asociados (IA) located in Santa Cruz de la Sierra. Founded in 1991, IA operates with six Partners and more than 40 professionals, offering full-service legal capabilities in arbitration, banking, corporate and commercial, civil law, dispute resolution, immigration, intellectual property, foreign investment, mergers and acquisitions, legal tech and startups, labor and real estate. The firm, consistently recognized by Chambers & Partners and the Legal 500, is led by Managing Partner Alonso Indacochea Pardo de Zela. “Our clients look to us to provide them with best-in-class service that enables them to succeed in today’s business environment. At IA, we changed the chip and became liquid lawyers, legal and business-oriented professionals with an open mindset to adaptability,” said Alonso. “Our collaboration with Andersen Global will allow us to offer our clients th

Schlumberger Announces Redemption of 100% of Outstanding 2.40% Senior Notes Due 20221.12.2021 01:00:00 EET | Press release

As part of its ongoing commitment to debt reduction, Schlumberger Limited (“Schlumberger”) today announced that Schlumberger Investment SA, an indirect wholly-owned subsidiary of Schlumberger (“SISA”), will redeem the entire outstanding principal amount of its 2.40% Senior Notes due 2022 (CUSIP Nos. 806854AD7 / L81445AD7; and ISIN Nos. US806854AD77 / USL81445AD75) (the “Notes”). The redemption date for the Notes is May 2, 2022 (the “Redemption Date”). The aggregate principal amount of the Notes outstanding is $1,000,000,000. SISA has deposited sufficient funds with The Bank of New York Mellon, the trustee under the indenture governing the Notes, to satisfy and discharge the Notes and the indenture with respect to the Notes (including payment of the February 1, 2022 interest payment with respect to the Notes and the redemption price payable on the Redemption Date), and the trustee has acknowledged such satisfaction and discharge. The Notes will be redeemed on the Redemption Date at a re

ITT’s Connector Business Introduces Veam MOVE-MOD™, Delivering True Modularity in Circular Interconnects30.11.2021 19:03:00 EET | Press release

November 30, 2021-- ITT Inc.’s (NYSE: ITT) connector business introduces its ruggedized, modular circular series Veam MOVE-MOD™. The flexible design delivers power, signal, and data in a single connector by utilizing a range of snap-in modules with various contact layouts to match individual system requirements. Developed for use in harsh environments, these ultra-durable connectors are suitable for a wide range of applications, including rail, heavy and off-road vehicles, alternative energy and infrastructure, robotics, and other industrial equipment. “Our customers have relied on Veam connectors to overcome their critical challenges for more than 60 years. MOVE-MOD is a next-generation solution designed to meet their evolving needs,” says Ellen McMillan, Vice President and General Manager Europe, ITT Connect and Control Technologies. “The modular nature of these innovative connectors give long-term flexibility to adapt, convert and expand connectivity post-design-in by simply swappin

Interactive Brokers Expands Tools for Global Investors30.11.2021 18:00:00 EET | Press release

Interactive Brokers Group (Nasdaq: IBKR), a global brokerage firm, today introduced GlobalAnalyst, a new tool that lets investors compare the relative valuations and financial metrics of stocks globally. GlobalAnalyst is designed for investors interested in international portfolio diversification to discover undervalued companies that may have greater growth potential. Recognizing that it can be challenging for investors to evaluate the relative merits of stocks traded in different currencies, Interactive Brokers created a simple yet powerful tool to compare any number of stocks by various metrics in one of 27 currencies of the user’s choice. Similarly, users may buy and sell and follow these stocks in the currency of their choice, all in one account on one screen. Using GlobalAnalyst, investors can search for stocks by region, country, industry, market capitalization and currency to identify undervalued stocks worldwide. A table displays current market and various financial metrics, s

New 7197PCP-DIN-NX Controller Improves Operational Efficiency by Allowing Centralized Control of Volumetric Dispensing Pumps30.11.2021 17:15:00 EET | Press release

Nordson EFD , a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces the 7197PCP-DIN-NX controller for 797PCP progressive cavity pumps. This controller provides Ethernet connection with Transmission Control Protocol / Internet Protocol (TCP/IP) for Smart Factory and Industry 4.0 manufacturing integration. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211130005031/en/ Improve operational efficiency by programming 797PCP volumetric dispensing pumps directly from a PLC via 7197PCP-DIN-NX controllers. (Photo: Business Wire) “This is enabling technology that allows our customers to be more lean, more efficient, more productive and more versatile as we prepare to enter fourth industrial revolution,” said Claude Bergeron, Senior Product Line Manager, Nordson EFD. “By helping manufacturers prepare, we ensure they won’t get left behind as Smart Factories transfer significant value to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom